(AKAO) Achaogen got mixed news this morning as the FDA approved its drug... and at the same time sent the company the dreaded CRL—Complete Response Letter. AKAO’s antibiotic, plazomicin, was submitted for approval in TWO indications — complicated urinary tract infections, as well as bloodstream infections. The former got the nod, the latter got the rod. Shares are down 20%. Anyone know of a new class of antibiotics that also has anti-inflammation properties?